1 |
Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ,Murphy WJ, Sayers TJ. The Proteasome InhibitorBortezomib (Velcade) Sensitizes Some Human TumorCells to Apo2L/TRAIL-Mediated Apoptosis. Ann N YAcad Sci 2005, 1059, 160-167
DOI
ScienceOn
|
2 |
Goldberg AL, Stein R, Adams J. New insights intoproteasome function: from archaebacteria to drugdevelopment. Chem Biol 1995, 2, 503-508
DOI
ScienceOn
|
3 |
Hammond EM, Giaccia AJ. The role of p53 inhypoxia-induced apoptosis. Biochem Biophys ResCommun 2005, 331, 718-725
DOI
ScienceOn
|
4 |
Inoue T, Shiraki K, Fuke H, Yamanaka Y, MiyashitaK, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K,Nakano T. Proteasome inhibition sensitizes hepatocellularcarcinoma cells to TRAIL by suppressingcaspase inhibitors and AKT pathway. Anticancer Drugs2006, 17, 261-268
DOI
ScienceOn
|
5 |
Ishizawa J, Yoshida S, Oya M, Mizuno R, ShinojimaT, Marumo K, Murai M. Inhibition of the ubiquitinproteasomepathway activates stress kinases andinduces apoptosis in renal cancer cells. Int J Oncol2004, 25, 697-702
PUBMED
|
6 |
Lim ML, Lum MG, Hansen TM, Roucou X, Nagley P. On the release of cytochrome c from mitochondriaduring cell death signaling. J Biomed Sci 2002, 9, 488-506
PUBMED
|
7 |
Mlynarczuk I, Hoser G, Grzela T, Stoklosa T,Wojcik C, Malejczyk J, Jakobisiak M. Augmentedpro-apoptotic effects of TRAIL and proteasomeinhibitor in human promonocytic leukemic U937 cells.Anticancer Res 2001, 21, 1237-1240
PUBMED
|
8 |
Nawrocki ST, Carew JS, Pino MS, Highshaw RA,Dunner K Jr, Huang P, Abbruzzese JL, McConkeyDJ. Bortezomib sensitizes pancreatic cancer cells toendoplasmic reticulum stress-mediated apoptosis. CancerRes 2005, 65, 11658-11666
DOI
ScienceOn
|
9 |
Pitti RM, Marsters SA, Ruppert S, Donahue CJ,Moore A, Ashkenazi A. Induction of apoptosis byApo-2 ligand, a new member of the tumor necrosisfactor cytokine family. J Biol Chem 1996, 271, 12687-12690
DOI
ScienceOn
|
10 |
Seol DW, Billiar TR. Cysteine 230 modulates tumornecrosis factor-related apoptosis-inducing ligand activity.Cancer Res 2000, 60, 3152-3154
PUBMED
|
11 |
Walczak H, Miller RE, Ariail K, Gliniak B, GriffithTS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT,Schuh JC, Lynch DH. Tumoricidal activity of tumornecrosis factor-related apoptosis-inducing ligand invivo. Nat Med 1999, 5, 157-163
DOI
ScienceOn
|
12 |
An WG, Hwang SG, Trepel JB, Blagosklonny MV.Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis areindependent markers of proteasome inhibition. Leukemia 2000, 14, 1276-1283
DOI
ScienceOn
|
13 |
Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, HanST, Park JW, Kwon TK. Influence of p53 andp21Waf1 expression on G2/M phase arrest of colorectalcarcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 2004, 24, 935-941
PUBMED
|
14 |
Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ,Adams J, Jiang JD, Muggia FM, Perez-Soler R. PS-341, a novel proteasome inhibitor, induces Bcl-2phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002,1, 841-849
PUBMED
|
15 |
Newmeyer DD, Ferguson-Miller S. Mitochondria:releasing power for life and unleashing the machineriesof death. Cell 2003, 112, 481-490
DOI
PUBMED
ScienceOn
|
16 |
He Q, Huang Y, Sheikh MS. Proteasome inhibitorMG132 upregulates death receptor 5 and cooperateswith Apo2L/TRAIL to induce apoptosis in Baxproficientand -deficient cells. Oncogene 2004, 23,2554-2558
DOI
ScienceOn
|
17 |
Coux O, Tanaka K, Goldberg AL. Structure andfunctions of the 20S and 26S proteasomes. Annu RevBiochem 1996, 65, 801-847
DOI
ScienceOn
|
18 |
Hansson LO, Friedler A, Freund S, Rudiger S,Fersht AR. Two sequence motifs from HIF-1alphabind to the DNA-binding site of p53. Proc Natl AcadSci USA 2002, 99, 10305-10309
DOI
ScienceOn
|
19 |
Lashinger LM, Zhu K, Williams SA, Shrader M,Dinney CP, McConkey DJ. Bortezomib abolishestumor necrosis factor-related apoptosis-inducing ligandresistance via a p21-dependent mechanism in humanbladder and prostate cancer cells. Cancer Res 2005, 65,4902-4908
DOI
ScienceOn
|
20 |
Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y,El-Deiry WS. Enhanced TRAIL sensitivity by p53overexpression in human cancer but not normal celllines. Int J Oncol 2001, 18, 241-247
PUBMED
|
21 |
Chen JJ, Chou CW, Chang YF, Chen CC.Proteasome inhibitors enhance TRAIL-induced apoptosisthrough the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53activation. J Immunol 2008, 180, 8030-8039
DOI
|
22 |
Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK,Shin HC, Sung YC, Oh BH. 2.8 A resolution crystalstructure of human TRAIL, a cytokine with selectiveantitumor activity. Immunity 1999, 11, 253-261
DOI
ScienceOn
|
23 |
Hougardy BM, Maduro JH, van der Zee AG, deGroot DJ, van den Heuvel FA, de Vries EG, de JongS. Proteasome inhibitor MG132 sensitizes HPV-positivehuman cervical cancer cells to rhTRAIL-inducedapoptosis. Int J Cancer 2006, 118, 1892-1900
DOI
ScienceOn
|
24 |
Hymowitz SG, Christinger HW, Fuh G, Ultsch M,O'Connell M, Kelley RF, Ashkenazi A, de Vos AM.Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell1999, 4, 563-571
DOI
ScienceOn
|
25 |
Yan XB, Yang DS, Gao X, Feng J, Shi ZL, Ye Z.Caspase-8 dependent osteosarcoma cell apoptosisinduced by proteasome inhibitor MG132. Cell Biol Int 2007, 31, 1136-1143
DOI
ScienceOn
|
26 |
Griffith TS, Anderson RD, Davidson BL, WilliamsRD, Ratliff TL. Adenoviral-mediated transfer of theTNF-related apoptosis-inducing ligand/Apo-2 ligandgene induces tumor cell apoptosis. J Immunol 2000,165, 2886-2894
DOI
|
27 |
Santer FR, Bacher N, Moser B, Morandell D,Ressler S, Firth SM, Spoden GA, Sergi C, Baxter RC, Jansen-Durr P, Zwerschke W. Nuclear insulinlikegrowth factor binding protein-3 induces apoptosisand is targeted to ubiquitin/proteasome-dependentproteolysis. Cancer Res 2006, 66, 3024-3033
DOI
ScienceOn
|
28 |
King RW, Deshaies RJ, Peters JM, Kirschner MW.How proteolysis drives the cell cycle. Science 1996,274, 1652-1659
DOI
PUBMED
ScienceOn
|
29 |
Kroemer G, Reed JC. Mitochondrial control of celldeath. Nat Med 2000, 6, 513-519
DOI
ScienceOn
|
30 |
Drexler HC. Activation of the cell death program byinhibition of proteasome function. Proc Natl Acad SciUSA 1997, 94, 855-860
DOI
ScienceOn
|
31 |
Voortman J, Resende TP, Abou El Hassan MA,Giaccone G, Kruyt FA. TRAIL therapy in non-smallcell lung cancer cells: sensitization to death receptormediatedapoptosis by proteasome inhibitor bortezomib.Mol Cancer Ther 2007, 6, 2103-2112
DOI
ScienceOn
|
32 |
Lu M, Dou QP, Kitson RP, Smith DM, GoldfarbRH. Differential effects of proteasome inhibitors on cellcycle and apoptotic pathways in human YT and Jurkatcells. J Cell Biochem 2006, 97, 122-134
DOI
ScienceOn
|
33 |
Wiley SR, Schooley K, Smolak PJ, Din WS, HuangCP, Nicholl JK, Sutherland GR, Smith TD, RauchC, Smith CA, Goodwin RG Identification andcharacterization of a new member of the TNF familythat induces apoptosis. Immunity 1995, 3, 673-682
DOI
ScienceOn
|
34 |
Wente MN, Eibl G, Reber HA, Friess H, Buchler MW, Hines OJ. The proteasome inhibitor MG132induces apoptosis in human pancreatic cancer cells.Oncol Rep 2005, 14, 1635-1638
PUBMED
|
35 |
Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADDinteractingprotease, in Fas/APO-1- and TNF receptorinducedcell death. Cell 1996, 85, 803-815
DOI
ScienceOn
|
36 |
Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H. Proteasomeinhibition sensitizes hepatocellular carcinoma cells, butnot human hepatocytes, to TRAIL. Hepatology 2005,42, 588-597
DOI
ScienceOn
|
37 |
Pagano M. Cell cycle regulation by the ubiquitinpathway. FASEB J 1997, 11, 1067-1075
DOI
PUBMED
|